Literature DB >> 32809300

Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors.

Namita Pandey1, Gunjan Tyagi2, Prabhjot Kaur1, Shrikant Pradhan1, Manchikatla Venkat Rajam1, Tapasya Srivastava3.   

Abstract

BACKGROUND/AIMS: The hypoxic microenvironment in NSCLC has been widely accepted as a contributor to both therapeutic resistance and tumor progression. In this study, we have explored Allicin, a key organosulfur compound present in garlic for its previously unreported effectiveness in the heterogeneous hypoxic tumor microenvironment of NSCLC.
METHODS: The effect of Allicin on the viability of NSCLC cells was determined by MTT assay. To determine the migration rate of treated cells compared to the control, scratch and transwell migration assays were performed. Flowcytometry was done to explore cell cycle distribution, apoptosis and ROS production in cells. Fluorescence microscopy was used to examine autophagy and DNA damage in cells. Dot blot was done to check genome wide methylation. RNA expression was detected by RT-PCR and protein expression by western blotting.
RESULTS: Allicin significantly decreases cell viability, proliferation and migration of NSCLC cells in both normoxia and hypoxia. It elicits both apoptosis and autophagy pathway in A549 cells by ROS accumulation and facilitating S/G2-M phase arrest in both normoxia as well as hypoxia. We suggest that ROS/MAPK and ROS/JNK signaling pathway together govern the cytotoxic effect of allicin in NSCLC cells. Notably, allicin suppresses the expression of HIF-1α and HIF-2α in hypoxic cells, pointing towards a mechanism of its effectiveness in hypoxia. A long term passive demethylation was observed, with decreased mC and no change in TET expression, thereby ruling out active demethylation by allicin. Furthermore, allicin synergistically enhances growth inhibitory activity of low dose cisplatin to effectively overcome hypoxia induced cisplatin resistance in A549 cells.
CONCLUSION: Altogether, our results elucidate a potential use of allicin in sensitizing hypoxic and chemoresistant NSCLC to cisplatin-based chemotherapy and provide new, affordable therapeutic strategy with reduced side effects. © Copyright by the Author(s). Published by Cell Physiol Biochem Press.

Entities:  

Keywords:  NSCLC; Hypoxia; Allicin; Reactive Oxygen Species (ROS); Cisplatin

Mesh:

Substances:

Year:  2020        PMID: 32809300     DOI: 10.33594/000000253

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

1.  Ubiquitin-specific protease 35 (USP35) mediates cisplatin-induced apoptosis by stabilizing BIRC3 in non-small cell lung cancer.

Authors:  Chunyan Liu; Zhaobo Chen; Xiaoyan Ding; Yun Qiao; Bing Li
Journal:  Lab Invest       Date:  2022-01-12       Impact factor: 5.662

Review 2.  Role of Phytochemicals in Perturbation of Redox Homeostasis in Cancer.

Authors:  Shreyas Gaikwad; Sanjay K Srivastava
Journal:  Antioxidants (Basel)       Date:  2021-01-09

Review 3.  Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.

Authors:  Sepideh Mirzaei; Kiavash Hushmandi; Amirhossein Zabolian; Hossein Saleki; Seyed Mohammad Reza Torabi; Adnan Ranjbar; SeyedHesam SeyedSaleh; Seyed Omid Sharifzadeh; Haroon Khan; Milad Ashrafizadeh; Ali Zarrabi; Kwang-Seok Ahn
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

4.  Escape From Cisplatin-Induced Senescence of Hypoxic Lung Cancer Cells Can Be Overcome by Hydroxychloroquine.

Authors:  Aleksandra Olszewska; Agata Borkowska; Monika Granica; Justyna Karolczak; Bartosz Zglinicki; Claudine Kieda; Halina Was
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

5.  Allicin Inhibits Osteosarcoma Growth by Promoting Oxidative Stress and Autophagy via the Inactivation of the lncRNA MALAT1-miR-376a-Wnt/β-Catenin Signaling Pathway.

Authors:  Wenpeng Xie; Wenjie Chang; Xiaole Wang; Fei Liu; Xu Wang; Daotong Yuan; Yongkui Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-06-24       Impact factor: 7.310

Review 6.  Combination Anticancer Therapies Using Selected Phytochemicals.

Authors:  Wamidh H Talib; Dima Awajan; Reem Ali Hamed; Aya O Azzam; Asma Ismail Mahmod; Intisar Hadi Al-Yasari
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

Review 7.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

8.  MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1α axis.

Authors:  Shan Hu; Peng Cao; Kangle Kong; Peng Han; Yu Deng; Fan Li; Bo Zhao
Journal:  J Transl Med       Date:  2021-05-27       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.